ALBLU.PA Bluelinea SA

Healthcare Health Care Equipment & Supplies Euronext Paris
0.0600 EUR
Close of Nov 5, 2026
0.0400 0.4080
Market cap
EUR 1.75M
P/E
-
P/B
1.52x
ROE
-627.9%
Dividend yield
-
Fundamental score
0.3/5

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is ALBLU.PA undervalued?

Graham number

The Graham number of Bluelinea SA cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Bluelinea SA fundamental analysis

1 of 11 checks passed

ROE 0/2

The stock's ROE indicates a negative return (-115.75%) on shareholders' equity, suggesting poor financial performance.

ROA 0/2

The stock's ROA (-20.61%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

PBV 0/2

The stock's elevated P/BV ratio (3.52x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

DER 1/2

The stock maintains a fair debt to equity ratio (63%), indicating a reasonable balance between the money it owes and the ownership it possesses.

Revenue Growth 0/2

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

Net Profit Growth 0/2

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

Assets Growth 0/2

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

Graham Number 0/1

The Graham number analysis indicates that this company's stock price is likely overpriced, raising concerns about its investment potential.

Dividend Growth 0/2

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

Dividend 0/2

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

Buffet Intrinsic Value 0/1

The company's stock appears overvalued (-7) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Bluelinea SA stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Bluelinea SA

Bluelinea Société Anonyme provides health services for elderly and disabled people in France. It offers seniors and home services, including day and night family, and elder support related services. The company also provides connected establishments services that protect residents while assisting caregivers and staff in shared accommodation between seniors, serviced residences, EHPADs, specialized disability centers, and health establishments. Bluelinea Société Anonyme was i…

Full company profile